91–100 of 267 posts
Earlier quoted context omitted.
Are there other nations which have less demanding requirements, but still decent vetting? Why can't these kinds of ideas go there?
My scientist friends tell me China is paying well, making funding available, and has a lower go-to-market burden. Innovation appears to be literally moving to China as talent is being drained away from the US & Europe.
If this could be used to fight bacteria resistant to antibiotics then it is the start of something fantastic.
If it can be used to fight also diseases in animals (e.g.: foot & mouth disease in cattle) or plants (e.g.: citrus cancer) then it is even bigger.
Back in 2011, there was an announcement from MIT about a new approach to a broad-spectrum antiviral that appeared to work.[1] This goes way beyond an AIDS-specific cure. But it was at MIT Lincoln Labs, which doesn't usually do bio. So the researcher moved to Draper Labs, but didn't get much funding. Then that funding ran out. Now the guy behind this is trying to get funding on Indiegogo.[3] The problem seems to be th…
Given billionaires running their own space programs it makes me wonder why there aren't more billionaires running biologic research companies. Between life extension and immunity to (or protection from) really pathological conditions it seems like their interests would be aligned with folks like this.
It's awesome that this is possible. Right now HIV infections are basically a minor nuisance, provided you're taking the appropriate medication, but this bodes well for future treatment of viral infections.
>Right now HIV infections are basically a minor nuisance, provided you're taking the appropriate medication The cost of treating an HIV+ person in the US is roughly $400K over the course of their expected lifetime. This is more than a nuisance sum. HIV treatment can also significantly affect quality of life.It is not yet time to become blase.
Back in 2011, there was an announcement from MIT about a new approach to a broad-spectrum antiviral that appeared to work.[1] This goes way beyond an AIDS-specific cure. But it was at MIT Lincoln Labs, which doesn't usually do bio. So the researcher moved to Draper Labs, but didn't get much funding. Then that funding ran out. Now the guy behind this is trying to get funding on Indiegogo.[3] The problem seems to be th…
Given billionaires running their own space programs it makes me wonder why there aren't more billionaires running biologic research companies. Between life extension and immunity to (or protection from) really pathological conditions it seems like their interests would be aligned with folks like this.
Earlier quoted context omitted.
This is the type of innovation we exchange for a sense of absolute security in having highly-vetted decade-long bio R&D and extensive backlogs at the FDA for approvals to sell products on the market. It's go big or go home because the regulatory risk/timeline is so extensive. Most of these things die quietly or never get started so we never really see the true costs of what it takes to push the pharma world forward.…
Are there other nations which have less demanding requirements, but still decent vetting? Why can't these kinds of ideas go there?
Maybe you can get approved in Australia or Sweden, but that will pay negligible sums compared to getting into the US market.
Back in 2011, there was an announcement from MIT about a new approach to a broad-spectrum antiviral that appeared to work.[1] This goes way beyond an AIDS-specific cure. But it was at MIT Lincoln Labs, which doesn't usually do bio. So the researcher moved to Draper Labs, but didn't get much funding. Then that funding ran out. Now the guy behind this is trying to get funding on Indiegogo.[3] The problem seems to be th…
Back in 2011, there was an announcement from MIT about a new approach to a broad-spectrum antiviral that appeared to work.[1] This goes way beyond an AIDS-specific cure. But it was at MIT Lincoln Labs, which doesn't usually do bio. So the researcher moved to Draper Labs, but didn't get much funding. Then that funding ran out. Now the guy behind this is trying to get funding on Indiegogo.[3] The problem seems to be th…
Given billionaires running their own space programs it makes me wonder why there aren't more billionaires running biologic research companies. Between life extension and immunity to (or protection from) really pathological conditions it seems like their interests would be aligned with folks like this.
There are plenty of foundations and the like though. The Schwartz Foundation funds a lot of neuroscience (particularly computational), but through grants to universities and researchers; Jerry Schwartz isn't really spending any time at the bench.
For basic research, this might make more sense. We know that, in principle, rockets can be built. Improving them isn't easy, but with enough time/money/effort, it can be done. For things like life extension, we don't know if it can be done, nor do we know the things we'd need to know to decide that (recuse as needed here). It'd be better to fund a broad portfolio of ideas than focus on your own enterprise.
It's also possible for these engineering-based companies to make money en route to their goal. Mars would be awesome, but there's money to be made in geosync or even low earth orbit too, which helps keep the business going. In contrast, there's no market for 1/3 of a possible antibiotic.
From the abstract: Intravenously injected quadruplex sgRNAs/saCas9 AAV-DJ/8 excised HIV-1 proviral DNA and significantly reduced viral RNA expression in several organs/tissues of Tg26 mice. In EcoHIV acutely infected mice, intravenously injected quadruplex sgRNAs/saCas9 AAV-DJ/8 reduced systemic EcoHIV infection, as determined by live bioluminescence imaging. Can a mod change the title to reflect the findings? The or…
For anyone unfamiliar with CRISPR, I strongly recommend this quick introduction video from Kurzgesagt on YouTube: https://www.youtube.com/watch?v=jAhjPd4uNFY
https://www.youtube.com/watch?v=k99bMtg4zRk
As fun as it is, Tim Blais works hard to make hardcore science engaging.